Press release
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
- In the TRuE-AD3 trial, children (age ≥2
About this update from Incyte Corporation
[{"type":"text","content":"\n- In the TRuE-AD3 trial, children (age ≥2 to","length":107,"tagName":"div"}]